Burnett, B., Pillai, L., Bitto, A., Squadrito, F., & Levy, R. Evaluation of CYP450 inhibitory effects and steady-state pharmacokinetics of genistein in combination with cholecalciferol and citrated zinc bisglycinate in postmenopausal women. International Journal of Women’s Health, 3, 139-50. https://doi.org/10.2147/IJWH.S19309 (Original work published 2011)

Burnett, B., Bitto, A., Altavilla, D., Squadrito, F., Levy, R., & Pillai, L. Flavocoxid inhibits phospholipase A2, peroxidase moieties of the cyclooxygenases (COX), and 5-lipoxygenase, modifies COX-2 gene expression, and acts as an antioxidant. Mediators of Inflammation, 2011, 385780. https://doi.org/10.1155/2011/385780 (Original work published 2011)

Levy, R., Khokhlov, A., Kopenkin, S., Bart, B., Ermolova, T., Kantemirova, R., … Burnett, B. (2010). Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: a randomized multicenter controlled trial in subjects with osteoarthritis of the knee. Advances in Therapy, 27(10), 731-42. https://doi.org/10.1007/s12325-010-0064-z

Pillai, L., Levy, R., Yimam, M., Zhao, Y., Jia, Q., & Burnett, B. (2010). Flavocoxid, an anti-inflammatory agent of botanical origin, does not affect coagulation or interact with anticoagulation therapies. Advances in Therapy, 27(6), 400-11. https://doi.org/10.1007/s12325-010-0040-7

Pillai, L., Burnett, B., Levy, R., & Cooperative, G. G. S. (2010). GOAL: multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin. Current Medical Research and Opinion, 26(5), 1055-63. https://doi.org/10.1185/03007991003694522